CD274 and non-small cell lung carcinoma: While the 5‐year survival has improved from less than 5% a decade ago to over 25% in high (≥50%) PD‐L1‐expressing NSCLC, prognosis for many patients remains poor, emphasizing the need for more options that exploit novel biological pathways.3